Could a High-Fiber powder help kids with type 1 diabetes?
NCT ID NCT06198725
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a high-fiber supplement called Trimtab can help preserve beta-cell function in children aged 6 to 12 who were recently diagnosed with type 1 diabetes. For 12 weeks, participants will take the supplement daily, and researchers will measure C-peptide levels (a marker of insulin production) and gut bacteria changes. The goal is to see if a simple dietary change can slow the loss of insulin-making cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Trimtab (a high-fiber grain powder)
What this could lead to
If it works, this could point toward a dietary approach to help preserve insulin production in children with new-onset type 1 diabetes.
What could go wrong
This is an early-stage study with only 110 participants, and the intervention is a dietary supplement, not a drug. It may not show a clear benefit, and results may not apply to all children with type 1 diabetes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Fudan University
RECRUITINGShanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••